期刊文献+

晚期肾上腺皮质癌诊疗的临床分析

The diagnosis and treatment of advanced adrenocortical carcinoma
下载PDF
导出
摘要 目的 分析晚期肾上腺皮质癌的诊断和治疗.方法 评估2002 年1 月至2014 年5 月本院泌尿微创中心收治的10 例晚期肾上腺皮质癌患者的临床数据,其中,男5 例,女5 例.结果 患者平均年龄为53.3 岁(31 ~ 85 岁),肿瘤最大直径为(14.4±5.1)cm.10 例患者中9 例行开放手术治疗,其中6 例达到肿瘤完全切除.所有患者均为临床Ⅳ期,其中T4N1M1 4 例,T4N1M0 3 例,T3N1M0 2 例,T4N0M0 1 例.随访3 ~ 18 个月,患者平均生存期为7.5 个月,1 年总体生存率为22.2%,2 年总体生存率为0.0%.3 例患者术后行联合化疗,但并未观察到明显的治疗效果.结论 肾上腺皮质癌是-种罕见的恶性肿瘤,晚期肾上腺皮质癌临床预后极差.对于晚期肾上腺皮质癌手术方式应优先选择开放手术.值得注意的是手术难度和术中出血风险较大,患者预后较差,应结合临床实际情况谨慎把握手术指征. Objective To investigate the diagnosis and treatment of patients with advanced adrenocortical carcinoma. Method 10 patients diagnosed with advanced adrenocortical carcinoma from January 2002 to May 2014 were evaluated. The clinic opathological data of 10 cases of advanced adrenocortical carcinoma were retrospectively analyzed, including 5 men and 5 women. Result The average age was 53.3 years, ranged from 31 to 85 years, with the tumor diamer of(14.4±5.1) cm. 9 cases of them were under open surgery, 6 cases of them underwent complete resection. All of them was stage Ⅳ. There was 4 cases of stage T4N1M1, 3 cases of stage T4N1M0, 2 cases of stage T3N1M0 and 1 case of stage T4N0M0. The mean survival time was 7.5 months after the follow up from 3 to 18 months. The overall survival rates were 22.2% in first year and 0.0% in second year. Although chemotherapy was given in 3 of them, no significant response was observed. ConclusionAdrenal cortical carcinoma is a rare malignant neoplasm with poor prognosis, especially in advanced cases, the open operation is the best way for patients of advanced adrenocortical carcinoma. The surgery is difficult, with high risk of bleeding and very poor prognosis, so the indications for surgery need to be treated carefully.
出处 《中国医学前沿杂志(电子版)》 2015年第8期17-19,共3页 Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词 肾上腺恶性肿瘤 临床特征 手术 预后 Adrenal malignant tumor Clinic opathological feature Surgery Prognosis
  • 相关文献

参考文献3

二级参考文献53

  • 1Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal corti- cal carcinoma in the United States [ J ]. Surgery, 2006,140 ( 6 ) : 914-920.
  • 2Fulmer BR. Diagnosis and management of adrenal cortical carcino- ma[ J]. Curr Urol Rep,2007,8( 1 ) :77-82.
  • 3Kirschner LS. Emerging treatment strategies ior adrenocortical car- cinoma : a new hope [ J ]. J Clin Endocrinol Metab, 2006,91 ( 1 ) : 14-21.
  • 4Menon V, Krishnamurthy SV. Adrenocortical carcinomas :a 12-year clinicopathologic study of 15 cases[ J ]. Indian J Pathol Microbiol, 2006,49 ( 1 ) :7-11.
  • 5Soon PS, McDonald KL, Robinson BG, et al. Molecular markers and the pathogenesis of adrenocortical cancer [ J ]. Oncologist, 2008,13(5) :548-561.
  • 6Rodfiguez-Galindo C, Figueiredo BC, Zambetti GP, et al. Biology, clinical characteristics, and managementof adrenocortical tumors in children[ J]. Pediatr Blood Cancer,2005,45 (3) :265-273.
  • 7Ribeiro RC ,Sandrini F,Figueiredo B, et al. An inherited p53 mu- tation that contributes in a tissue-specific manner to pediatric adre- nal cortical carcinoma[J], Proc Natl Aead Sei U S A,2001,98 ( 16 ) :9330-9335.
  • 8Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocorti- cal tumors [ J ]. J Clin Endocrinol Metab, 2001, 86 ( 10 ) : 4970-4973.
  • 9Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortieal tumors uncovered by DNA microarray a- nalysis[ J]. Am J Pathol,2003,162(2) :521-531.
  • 10Bourdeau I, Antonini SR, Lacroix A, et al. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators [ J ]. Oncogene ,2004,23 ( 8 ) : 1575-1585.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部